Abeona Therapeutics (ABEO) Short term Debt (2010 - 2026)

Abeona Therapeutics' Short term Debt history runs 14 years deep, the most recent figure standing at $13.3 million for Q1 2026.

• In Q1 2026, Short term Debt rose 63.64% year-over-year to $13.3 million; the TTM figure through Mar 2026 stood at $13.3 million (up 63.64% YoY), while the FY2025 annual figure was $12.2 million, up 106.24% from the prior year.
• Short term Debt for Q1 2026 stood at $13.3 million, up from $12.2 million in the prior quarter.
• The five-year high for Short term Debt was $13.3 million in Q1 2026, with the low at $2.2 million in Q2 2024.
• The 5-year median for Short term Debt is $4.9 million (2022), against an average of $6.5 million.
• Peak annual rise in Short term Debt reached 174.06% in 2022, while the deepest fall reached 85.7% in 2022.
• Abeona Therapeutics' Short term Debt stood at $4.9 million in 2022, then dropped by 6.93% to $4.6 million in 2023, then advanced by 29.39% to $5.9 million in 2024, then jumped by 106.24% to $12.2 million in 2025, then gained by 9.09% to $13.3 million in 2026.
• Business Quant data shows ABEO's Short term Debt at $13.3 million in Q1 2026, $12.2 million in Q4 2025, and $8.9 million in Q3 2025.